The FDA on March 23, 2017, granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.
Skin Cancer (Nonmelanoma)
In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.
In this interview we discuss a patient who experienced regression of BRAF-inhibitor-induced eruptive melanocytic nevi following concomitant addition of a MEK inhibitor.
Multiple abstracts on melanoma and skin cancer were reviewed at the ASCO Annual Meeting, with a focus on new treatment approaches in non-melanoma skin cancers, particularly basal cell carcinoma and Merkel cell carcinoma.